Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied as not FDA-approved for this use by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

## Anthem's "Not FDA-Approved" Denial on Semaglutide: Decoding the Off-Label Trap

When Anthem stamps a semaglutide claim with a "not FDA-approved for this indication" denial, the rejection is almost never about Ozempic or Rybelsus as molecules — both carry FDA approval for type 2 diabetes since 2017/2019. The denial is an indication-mismatch rejection generated by Anthem's pharmacy benefit logic (administered through CarelonRx, Anthem's in-house PBM since 2024) when the submitted ICD-10 diagnosis fails to match the approved label. The most common triggers: an E66.x obesity code submitted against Ozempic (label = T2DM only), an R73.03 prediabetes code, or a PCOS/metabolic-syndrome code with no concurrent E11.x. Anthem's Clinical UM Guideline CG-DRUG-110 (GLP-1 Receptor Agonists) and Medical Policy DRUG.00074 explicitly require a confirmed T2DM diagnosis (E11.x family) plus HbA1c ≥6.5% documented within the prior 12 months, or a fasting glucose ≥126 mg/dL on two occasions.

### Why "off-label" is not a clean denial

Anthem cannot reflexively deny every off-label use. Under ERISA 29 CFR §2560.503-1(g), the adverse benefit determination must specify the internal rule, guideline, or protocol relied upon and disclose it free of charge on request. If Anthem cites "not FDA-approved" without producing the specific CG-DRUG-110 criterion that failed, the denial is procedurally defective and ripe for remand. The Tenth Circuit's holding in *Pinto v. Aetna Life Ins. Co. (2014) makes clear that the burden of proving an experimental/non-approved exclusion sits with the plan, not the member — Anthem must affirmatively show the prescribed use falls outside the label and* outside compendia-supported off-label use.

### The compendia override most prescribers miss

Anthem's own DRUG.00074 language acknowledges coverage for off-label uses supported by DrugDex Level 1 / 2A, AHFS-DI, or NCCN Category 1/2A recommendations. Semaglutide for obesity with comorbid T2DM is supported across multiple compendia; for pure obesity, the correct product is Wegovy (semaglutide 2.4 mg) — submitting Ozempic for E66.01 will fail every time. If the patient has T2DM, resubmit with the E11.x as the primary diagnosis, attach the A1c lab within 12 months, and cite CG-DRUG-110 by name in the appeal letter.

### Tactical closing tip

File the level-one appeal through CarelonRx pharmacy appeals at 1-833-293-0659 (not Anthem medical appeals — wrong queue delays 14+ days). Include: (1) ICD-10 E11.9 or E11.65 on the prescription, (2) the qualifying A1c lab report, (3) a one-line attestation that the prescription matches the FDA-approved T2DM indication. If denied again, escalate to your state DOI — Anthem's CA, NY, and GA market conduct exams have flagged indication-coding denials as a pattern, and DOI complaints typically reverse within 30 days.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.